伊立替康联合卡培他滨治疗铂类耐药的复发上皮性卵巢癌的疗效及安全性分析

Clinical Efficacy and Safety of Irinotecan Combined with Capecitabine in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer

目的探讨伊立替康联合卡培他滨对铂类耐药的复发上皮性卵巢癌的疗效及副作用。方法对收入我院的复发上皮性卵巢癌患者以21天为1周期进行治疗。每1个周期的第1、8天给予患者伊立替康60mg/m^2静脉滴注、每天一次;每1个周期的第1、2周给予患者卡培他滨1250mg/m^2口服、每天两次,连续口服两周。每2个周期复查B超或CT进行疗效评价,并观察其毒副作用。结果共入组32例,可评估31例,其中完全缓解0例(0%),部分缓解10例(32.26%),未缓解21例(67.74%),客观缓解率32.26%(10/31例),无进展生存期5.3个月(1.5-14.1个月)。毒副作用多为轻中度,无治疗相关性死亡。结论伊立替康联合卡培他滨治疗铂类耐药的复发上皮性卵巢癌有较好的疾病控制率和安全性,可作为预期生存期3个月以上患者的可选治疗方案。

Objective To discuss the short-term clinical efficacy and side effects of irinotecan combined with capecitabine in treating platinum-resistant recurrent epithelial ovarian cancer.Methods Cases with recurrent epithelial ovarian cancer were enrolled and each treatment course lasted for 21 days;an intravenous drip of irinotecan 60mg/m^2 was given to the cases on the 1st and 8th day of each course and oral administration of 1250 mg/m^2 capecitabine tablets,twice a day,was made to the cases in the first 2 weeks of each course;reexaminations of B-ultrasound and CT were performed every 2 courses so as to observe the clinical efficacy and toxic side effects.Results Out of the 32 enrolled cases,31 cases were valid for the evaluation,including 0 case of complete response(CR,0%),10 of partial response(PR,32.26%)and 21 of no response(NR,67.74%);the objective response rate(ORR)was 32.26%(10/31),and the progression-free survival(PFS)was 5.3 months(1.5-14.1 months);most of the toxic side effects were mild or moderate and there was no treatment-related death.Conclusions Irinotecan combined with capecitabine is of good disease control rate and high safety for platinum-resistant recurrent epithelial ovarian cancer,and it is an optional treatment for those cases with life expectancy over 3 months.